Back to Search

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation


  • Protocol Number: 201912013
  • Principal Investigator: Dipersio, John
  • Cancer Types: Leukemia, Myeloma, and Hematologic, Siteman Kids- Pediatrics

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions